Stevie Olsen
Stevie Olsen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Alain Schoepfer
Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois University of Lausanne Lausanne Switzerland
1 shared publication - Amr Radwan
Regeneron Pharmaceuticals Inc., Tarrytown, NY
1 shared publication - Angela Khodzhayev
Regeneron Pharmaceuticals, Inc. , 777 Old Saw Mill River Rd, Tarrytown, NY 10591
1 shared publication - Arturo Benitez
Takeda Development Center Americas, Inc. Cambridge Massachusetts USA
1 shared publication - Dennis Dlugos
Departments of Neurology and Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
1 shared publication - Drishti Shah
IQVIA, Falls Church, Virginia
1 shared publication
Latest Publications
- Open Access
- 22 September 2025
- Published by Wiley in Epilepsia Open
- Vol. 10 (6) , 1783-1797
Nonseizure symptoms and broader seizure impacts in patients with Dravet syndrome and Lennox–Gastaut syndrome in clinical practice settings: Results from a multinational survey
Objective: To assess the burden of Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS), including managing seizure and nonseizure symptoms, on patients and caregivers. Methods: Data were drawn from the Adelphi Real World DS and LGS Disease Specific Programme™, a cross‐sectional survey in Asia (China, Japan), Europe (France, Germany, Italy, Spain, United Kingdom), and the United States of America between July 2022 and August 2023. Neurologists/pediatric neurologists reported demographics, clinical characteristics, and nonseizure symptoms for up to 10 consecutively consulting patients. Caregivers provided data on patient nonseizure symptoms, quality of life (QoL), satisfaction with treatment, and caregiver burden. Analyses were descriptive. Results: Physicians ( n = 259) reported data on 547 patients with DS and 811 with LGS. Caregivers ( n = 348) provided data on 157 patients with DS and 191 with LGS. In the previous 6 months, 51% of patients with DS experienced ≥1 seizure‐related injury and 61% experienced status epilepticus. For LGS, this was 50% and 43% of patients, respectively. Rates of moderate to very severe impairment in nonseizure symptoms were reported by physicians in learning/intellect (DS 69%; LGS 78%), verbal communication (DS 69%; LGS 71%), severity of developmental delay (DS 65%; LGS 68%), overall mental status (DS 57%; LGS 67%), and nonverbal communication (DS 61%; LGS 64%). Caregivers reported moderate to very severe impairment in learning/intellect (DS 53%; LGS 67%), severity of developmental delay (DS 52%; LGS 56%), verbal communication (DS 48%; LGS 48%), and nonverbal communication (DS 42%; LGS 45%). Caregivers reported nonseizure symptoms moderately to significantly impacted QoL for 56% of patients (DS 49%; LGS 61%); satisfaction with treatment rate was low for control over cognition/memory, verbal communication, and nonverbal communication impairment. Significance: In this study, considerable burden in DS and LGS management and care was driven by nonseizure symptoms, suggesting a need for treatments that manage the broad spectrum of disease symptoms. Plain Language Summary: We asked doctors and caregivers to tell us about the symptoms that patients with Dravet syndrome and Lennox–Gastaut syndrome have. We asked how the symptoms affect the lives of the patients as well as the caregivers. We found that seizures have a big impact on the health and well‐being of patients and caregivers. We also found that other symptoms not caused by seizures have a big impact on patients and their caregivers.
- 22 September 2025
- Published by Wiley in Epilepsia Open
- Vol. 10 (6) , 1783-1797
Open AccessNonseizure symptoms and broader seizure impacts in patients with Dravet syndrome and Lennox–Gastaut syndrome in clinical practice settings: Results from a multinational survey
Objective: To assess the burden of Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS), including managing seizure and nonseizure symptoms, on patients and caregivers. Methods: Data were drawn from the Adelphi Real World DS and LGS Disease Specific Programme™, a cross‐sectional survey in Asia (China, Japan), Europe (France, Germany, Italy, Spain, United Kingdom), and the United States of America between July 2022 and August 2023. Neurologists/pediatric neurologists reported demographics, clinical characteristics, and nonseizure symptoms for up to 10 consecutively consulting patients. Caregivers provided data on patient nonseizure symptoms, quality of life (QoL), satisfaction with treatment, and caregiver burden. Analyses were descriptive. Results: Physicians ( n = 259) reported data on 547 patients with DS and 811 with LGS. Caregivers ( n = 348) provided data on 157 patients with DS and 191 with LGS. In the previous 6 months, 51% of patients with DS experienced ≥1 seizure‐related injury and 61% experienced status epilepticus. For LGS, this was 50% and 43% of patients, respectively. Rates of moderate to very severe impairment in nonseizure symptoms were reported by physicians in learning/intellect (DS 69%; LGS 78%), verbal communication (DS 69%; LGS 71%), severity of developmental delay (DS 65%; LGS 68%), overall mental status (DS 57%; LGS 67%), and nonverbal communication (DS 61%; LGS 64%). Caregivers reported moderate to very severe impairment in learning/intellect (DS 53%; LGS 67%), severity of developmental delay (DS 52%; LGS 56%), verbal communication (DS 48%; LGS 48%), and nonverbal communication (DS 42%; LGS 45%). Caregivers reported nonseizure symptoms moderately to significantly impacted QoL for 56% of patients (DS 49%; LGS 61%); satisfaction with treatment rate was low for control over cognition/memory, verbal communication, and nonverbal communication impairment. Significance: In this study, considerable burden in DS and LGS management and care was driven by nonseizure symptoms, suggesting a need for treatments that manage the broad spectrum of disease symptoms. Plain Language Summary: We asked doctors and caregivers to tell us about the symptoms that patients with Dravet syndrome and Lennox–Gastaut syndrome have. We asked how the symptoms affect the lives of the patients as well as the caregivers. We found that seizures have a big impact on the health and well‐being of patients and caregivers. We also found that other symptoms not caused by seizures have a big impact on patients and their caregivers.
- Open Access
- 3 March 2025
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (2)
Burden of eosinophilic esophagitis in adult and adolescent patients: results from a real-world analysis
Summary: Background: Real-world data on the impact of eosinophilic esophagitis (EoE) in patients are limited. This study assessed clinical characteristics, healthcare resource utilization (HCRU), symptoms, comorbidities, and quality of life (QoL) of EoE patients. Methods: The multicountry cross-sectional survey, Adelphi EoE Disease Specific Programme™, collected physician and patient-reported data on clinical characteristics, HCRU, symptoms, comorbidities, and QOL of EoE patients with past/current proton pump inhibitor use and ongoing dysphagia-related symptoms (September to December 2020) at study entry. Results: Physicians provided clinical characteristics, symptom, comorbidity, and HCRU data for 412 patients (12–17 years: 8%; ≥18 years: 92%); and 161 of these patients (12–17 years: 6%; ≥18 years: 94%) provided symptom and QOL data. Of the 412 patients, 67% were male, with a mean (SD) age of 37.0 (15.3) years. Overall, 74% of patients were currently being treated with corticosteroids (12–17 years: 88%; ≥18 years: 73%); 25% of patients had a history of esophageal dilations (12–17 years: 19%; ≥18 years: 26%); and 30% of patients had EoE-related emergency room visit (12–17 years: 31%; ≥18 years: 30%) in the last year. Among the 161 patients, heartburn (69%) was the most commonly reported symptom; the greatest negative impacts on QOL were reported for dysphagia-related anxiety, social activities involving food, and maintaining friendships (EoE Impact Questionnaire scores [1–5, low to high impact]: 1.6–2.2 for both age groups). Conclusion: EoE patients continued to experience disease burden despite receiving treatment, highlighting the high unmet need for effective disease management in this population.
- 3 March 2025
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (2)
Open AccessBurden of eosinophilic esophagitis in adult and adolescent patients: results from a real-world analysis
Summary: Background: Real-world data on the impact of eosinophilic esophagitis (EoE) in patients are limited. This study assessed clinical characteristics, healthcare resource utilization (HCRU), symptoms, comorbidities, and quality of life (QoL) of EoE patients. Methods: The multicountry cross-sectional survey, Adelphi EoE Disease Specific Programme™, collected physician and patient-reported data on clinical characteristics, HCRU, symptoms, comorbidities, and QOL of EoE patients with past/current proton pump inhibitor use and ongoing dysphagia-related symptoms (September to December 2020) at study entry. Results: Physicians provided clinical characteristics, symptom, comorbidity, and HCRU data for 412 patients (12–17 years: 8%; ≥18 years: 92%); and 161 of these patients (12–17 years: 6%; ≥18 years: 94%) provided symptom and QOL data. Of the 412 patients, 67% were male, with a mean (SD) age of 37.0 (15.3) years. Overall, 74% of patients were currently being treated with corticosteroids (12–17 years: 88%; ≥18 years: 73%); 25% of patients had a history of esophageal dilations (12–17 years: 19%; ≥18 years: 26%); and 30% of patients had EoE-related emergency room visit (12–17 years: 31%; ≥18 years: 30%) in the last year. Among the 161 patients, heartburn (69%) was the most commonly reported symptom; the greatest negative impacts on QOL were reported for dysphagia-related anxiety, social activities involving food, and maintaining friendships (EoE Impact Questionnaire scores [1–5, low to high impact]: 1.6–2.2 for both age groups). Conclusion: EoE patients continued to experience disease burden despite receiving treatment, highlighting the high unmet need for effective disease management in this population.
- Open Access
Assessment of joint health in patients receiving prophylaxis for haemophilia A: a cross-sectional survey in five European countries
Objectives To evaluate joint health, pain and health-related quality of life (HRQoL) in patients with moderate/severe haemophilia A in Europe. Design Multinational, cross-sectional survey, with retrospective data collection. Data were taken from the Adelphi Real World Haemophilia Disease Specific Programme Wave II, using surveys completed by physicians and patients between February 2020 and May 2021. Setting Haematologists/haemato-oncologists and their patients in France, Germany, Italy, Spain and the UK. Participants Males aged ≥18 years with moderate or severe haemophilia A (baseline clotting factor level ≤5%), without existing inhibitors and currently receiving prophylaxis. Patients were grouped into those with or without haemophilia-affected joints (HAJs) based on bleeding, radiographic, surgical, mobility and joint pain data. Primary outcome measure Characterisation of humanistic and clinical outcomes in patients with or without HAJs. Results A total of 120 physicians provided data for 351 eligible patients; 209 (59.5%) patients had HAJs and 142 (40.5%) had no HAJs. Pain/discomfort was significantly different (p=0.01) and reported more frequently in the HAJ (85.7%) vs non-HAJ group (53.3%). Pain medication use was significantly higher in the HAJ versus non-HAJ group (73.2% vs 60.6%; p=0.01). Up to half of the patients with HAJs had synovitis (49.8%) or arthropathy (48.4%), and one-third had undergone joint surgery (35.4%). Overall health status was significantly worse in the HAJ versus non-HAJ group (mean (SD) EuroQol Visual Analogue Scale score: 65.5 (19.3) vs 81.1 (14.6); p=0.01). Conclusions In this multinational real-world study, nearly two-thirds of adults with moderate/severe haemophilia A without inhibitors experienced HAJs despite prophylaxis. Individuals with HAJs had higher rates of pain and pain medication use, and lower HRQoL compared with those without HAJs. These data indicate that HAJs represent a clinically relevant burden and early identification/monitoring and management of affected joints should be an important consideration to help prevent long-term joint morbidity.
Open AccessAssessment of joint health in patients receiving prophylaxis for haemophilia A: a cross-sectional survey in five European countries
Objectives To evaluate joint health, pain and health-related quality of life (HRQoL) in patients with moderate/severe haemophilia A in Europe. Design Multinational, cross-sectional survey, with retrospective data collection. Data were taken from the Adelphi Real World Haemophilia Disease Specific Programme Wave II, using surveys completed by physicians and patients between February 2020 and May 2021. Setting Haematologists/haemato-oncologists and their patients in France, Germany, Italy, Spain and the UK. Participants Males aged ≥18 years with moderate or severe haemophilia A (baseline clotting factor level ≤5%), without existing inhibitors and currently receiving prophylaxis. Patients were grouped into those with or without haemophilia-affected joints (HAJs) based on bleeding, radiographic, surgical, mobility and joint pain data. Primary outcome measure Characterisation of humanistic and clinical outcomes in patients with or without HAJs. Results A total of 120 physicians provided data for 351 eligible patients; 209 (59.5%) patients had HAJs and 142 (40.5%) had no HAJs. Pain/discomfort was significantly different (p=0.01) and reported more frequently in the HAJ (85.7%) vs non-HAJ group (53.3%). Pain medication use was significantly higher in the HAJ versus non-HAJ group (73.2% vs 60.6%; p=0.01). Up to half of the patients with HAJs had synovitis (49.8%) or arthropathy (48.4%), and one-third had undergone joint surgery (35.4%). Overall health status was significantly worse in the HAJ versus non-HAJ group (mean (SD) EuroQol Visual Analogue Scale score: 65.5 (19.3) vs 81.1 (14.6); p=0.01). Conclusions In this multinational real-world study, nearly two-thirds of adults with moderate/severe haemophilia A without inhibitors experienced HAJs despite prophylaxis. Individuals with HAJs had higher rates of pain and pain medication use, and lower HRQoL compared with those without HAJs. These data indicate that HAJs represent a clinically relevant burden and early identification/monitoring and management of affected joints should be an important consideration to help prevent long-term joint morbidity.